Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display

3784 - Chemotherapy alone or combined chemotherapy and involved field radiotherapy in favorable risk early-stage classical Hodgkin lymphoma-a 10 years experience


08 Oct 2016


Poster Display


Sheeraz Buriro


Annals of Oncology (2016) 27 (6): 313-327. 10.1093/annonc/mdw375


S. Buriro, A. Basit, A.S. Kazmi, F. Badar, A. Sidhu, A. Hameed

Author affiliations

  • Department Of Medical Oncology, Shaukat Khanum Memorial Cancer Hospital and Reserch Centre (SKM), 54550 - Lahore/PK


Abstract 3784


Early-stage Hodgkin lymphoma is divided into favorable and unfavorable disease. Trials for patients with limited-stage HL have demonstrated that treatment with chemotherapy plus involved-field radiation therapy (IFRT) and chemotherapy alone with Doxorubicin (Adriamycin), Bleomycin, Vinblastine, and Dacarbazine (ABVD) may both be acceptable options. The aim of this study was to determine the outcomes of favorable risk early-stage Hodgkin lymphoma treated either with chemotherapy alone or chemotherapy plus IFRT.


Retrospective study done on newly diagnosed patients of early-stage classical HL with favorable risk prognostic features. Patients were divided in 2 groups i.e chemotherapy alone or combined modality treatment (CMT) comprising of chemotherapy followed by radiotherapy. Baseline characteristics in both groups were compared using cross tab and chi square test. PFS and OS for both groups was calculated using survival curves.


Out of 101 patients, 71.3% were male. Sixty three (62.4%) patients received CMT and 38 (37.6%) patients had chemotherapy alone. Radiotherapy dose was 20 to 36 gray. Patients treated with CMT had OS compared to chemotherapy alone: 100% versus 91% at 5 years and 96% versus 81% at 10 years respectively (p = 0.03). PFS with CMT against chemotherapy alone at 5 years (98% versus 81%) and 10 years (82% versus 71%) (p = 0.01).


Patients treated with CMT had better progression free survival and overall survival compared to chemotherapy alone.

Clinical trial identification

Legal entity responsible for the study

Shaukat Khanum Memorial Cancer Hospital and research Centre, Lahore, Pakistan was responsible for the governance, coordination and running of the study.




All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings